Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bulanta
- Development stage
- Preclinical
- Lead developer
- GreenJay Therapeutics
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Bulanta is a DMA-free intravenous formulation of busulfan, a bifunctional DNA alkylating agent, being developed by GreenJay Therapeutics. Busulfan is traditionally used as a conditioning agent prior to hematopoietic stem cell transplantation (HSCT) for various hematologic malignancies and genetic disorders. Standard IV busulfan formulations utilize dimethylacetamide (DMA) as a solvent, which is associated with significant toxicities, including hepatic veno-occlusive disease (VOD) and neurotoxicity. Bulanta is designed to eliminate DMA-related toxicity while maintaining the therapeutic efficacy of busulfan. It is currently in IND-enabling studies for a wide range of indications, including leukemias (AML, CML, ALL), lymphomas (HL, NHL), multiple myeloma, and non-malignant conditions like sickle cell anemia, thalassemia, and Krabbe disease.
- Brand names
- Bulanta
- Other names
- DMA-free IV busulfanbusulfan
02
Targets
DNA
Beyond the preview
Go deeper on Bulanta.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bulanta.